ADMA raises FY2024-25 revenue guidance; preliminary Q4 rev $72-74M, FY rev $256-258M

ADMA BIOLOGICS, INC.

2023-FY EPS reported -$0.13 revenue$258,215,000

Q4 2023 preliminary revenue $72-74M; full year $256-258M.
FY2024 revenue guidance raised to >$320M from $290M; FY2025 to >$370M from $335M.
FY2024 net income expected >$60M (from $55M) and adjusted EBITDA ~$85M.
New growth: manufacturing yield enhancement and S. pneumonia hyperimmune globulin (potential peak revenue $300-500M).
ASCENIV label expansion via pediatric study progressing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported fourth quarter and full year 2023 results: revenue $72-74 Million. Guidance raised.

Period: fourth quarter and full year 2023
Revenue: $72-74 Million
Guidance: raised
Result: preliminary results

Exact text from the filing

ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update 4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-001194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.